Abstract
Objective: to study the dynamics of carbohydrate and lipid metabolism and markers of visceral obesity (VO) in patients with type 2 diabetes mellitus (T2DM) and obesity when using a fixed combination of alogliptin and pioglitazone. Material and methods. 30 patients with T2DM and obesity were examined. Indicators of carbohydrate and lipid metabolism and markers of VO (conicity index, index of lipid products accumulation, waist circumference to height ratio) were assessed initially and over time 6 months after the start of using alogliptin 25 mg and pioglitazone 30 mg. Results. When taking alogliptin and pioglitazone, patients with T2DM and obesity showed a compensation of fasting and postprandial hyperglycemia, an effective reduction in glycated hemoglobin and insulin resistance of peripheral tissues, and favorable changes in lipid metabolism with a positive effect on the calculated VO indices. Conclusions. The combination of alogliptin and pioglitazone can be recommended as a reliable and safe treatment regimen for patients with T2DM and obesity with the ability to correct major cardiovascular risk factors.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call